A putative therapeutic target in Huntington disease: P42858

Ablatotech Signals reports today on a putative therapeutic target — P42858 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in Huntington disease.

Background

The protein associated with UniProt accession P42858 is being investigated as a putative target that warrants experimental validation for its potential role in Huntington disease (HD). Huntington disease is a hereditary neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric disturbances. Understanding the involvement of P42858 in the pathophysiology of HD could open new avenues for therapeutic exploration, although its clinical relevance has yet to be established.

Data-mining rationale

The rationale for focusing on P42858 arises from the cross-referencing of reviewed human entries in UniProt related to Huntington disease. Notably, P42858 has been identified in expression-profiling studies, indicating its potential involvement in the disease. However, it is important to highlight that no Phase 1 or higher clinical programs have been registered for this candidate, suggesting a significant gap in its investigation as a therapeutic target.

Why prior analyses may have missed this

The analysis of expression data was conducted against zero microarray datasets in the NCBI Gene Expression Omnibus (GEO). This lack of available datasets may have limited the exploration of P42858's role in Huntington disease. Furthermore, many existing GEO datasets predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which are crucial for accurate multiple-testing corrections. This methodological limitation may have contributed to the underappreciation of P42858 in previous studies.

Reasoning for further validation

To further investigate the potential role of P42858 in Huntington disease, several experimental approaches are recommended: 1. Re-analyze any available matched GEO datasets using the limma package, applying a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to identify differentially expressed genes more accurately. 2. Validate the top differentially expressed genes, including P42858, through quantitative PCR (qPCR) in an independent cohort to confirm expression changes. 3. Assess the tissue specificity of P42858 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in the central nervous system. 4. Utilize STRING and OmniPath databases to explore the pathway context of P42858, examining its interactions and potential biological roles. 5. If validation is achieved, evaluate the druggability of P42858 through databases like DGIdb and ChEMBL to assess its potential as a therapeutic target.

References